Are cathepsin K inhibitors just another class of anti-resorptives?

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4329-4331

  Chambers, T J ^a   Tobias, J H ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BALICATIB; CATHEPSIN K; CATHEPSIN K INHIBITOR; DENOSUMAB; ODANACATIB; PARATHYROID HORMONE[1-34];

BONE DENSITY; BONE STRENGTH; DRUG EFFECT; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; NONHUMAN; NOTE; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CATHEPSIN K; HUMANS; OSTEOCLASTS; PYCNODYSOSTOSIS;

EID: 84887441062     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2630     Document Type: Note

References (10)

1. Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27: 509-523.
2. Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012; 27: 524-537.
3. Jerome C, Missbach M, Gamse R. Balicatib, a cathepsinKinhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2011;22: 3001-3011.
4. Eisman JA, BoneHG,Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: threeyear continued therapy and resolution of effect. J Bone Miner Res. 2011;26: 242-251.
5. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab. 2013;98: 571-580.
6. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123: 666-681.
7. Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone. 2008;42: 200-211.
8. Lean JM, Jagger CJ, Chambers TJ, Chow JW. Increased insulin-like growth factor I mRNA expression in rat osteocytes in response to mechanical stimulation. Am J Physiol. 1995;268:E318-E327.
9. Lau KH, Baylink DJ, Zhou XD, et al. Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity. Am J Physiol Endocrinol Metab. 2013;305:E271-E281.
10. Tobias JH, Chow JW, Chambers TJ. Opposite effects of insulin-like growth factor-I on the formation of trabecular and cortical bone in adult female rats. Endocrinology. 1992;131: 2387-2392.